Statin Use During Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Cancer
This study suggests an association between statin use during the CCRT period for NPC and potential enhancements in both OS and NPC-specific survival. Our findings indicate a possible survival benefit of rosuvastatin, atorvastatin, and lovastatin for patients with NPC undergoing CCRT. The observed dose-response relationship underscores the potential importance of higher statin use in mitigating NPC-specific mortality, but further research is needed to establish a definitive causal relationship.
Authors
- Szu‐Yuan Wu (ORCID: https://orcid.org/0000-0001-5637-558X)
- Ben‐Chang Shia (ORCID: https://orcid.org/0000-0003-2854-8361)
- Jung-Min Yu
- Kuan‐Chou Lin (ORCID: https://orcid.org/0000-0002-5143-2837)
- Wan‐Ming Chen (ORCID: https://orcid.org/0009-0009-6628-0635)
- Chia-Lun Chang
Institutions
- Fu Jen Catholic University (TW)
- Asia University (TW)
- Tzu Chi University (TW)
- Luodong Poh-Ai Hospital (TW)
- Ministry of Health and Welfare (TW)
- Wan Fang Hospital (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2024-11-01
- DOI
- https://doi.org/10.6004/jnccn.2024.7046
- Citations
- 1
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.29